National Nephrology $150 million eight-year notes talked at 9%-9¼%, pricing Thursday

By Paul A. Harris

St. Louis, Oct. 15 - Price talk is 9%-9¼% on National Nephrology Associates, Inc.'s upcoming sale of $150 million eight-year senior subordinated notes (B3/B-), according to a syndicate source.

The deal is expected to price on Thursday, the source added.

Banc of America Securities is running the books for the Rule 144A offering. JP Morgan and RBC are joint leads. Harris Nesbitt is co-manager.

The notes will be non-callable for four years.

National Nephrology will use proceeds to repay bank debt and to fund payment of the first phase of its acquisition of the Saint Barnabas assets.

The company is a Nashville-based provider of dialysis services.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.